FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889873881> ?p ?o ?g. }

• W2889873881 endingPage "3482" @default.
• W2889873881 startingPage "3476" @default.
• W2889873881 abstract "The swell of experimental imaging technologies to noninvasively measure immune checkpoint protein expression presents the opportunity for rigorous comparative studies toward identifying a gold standard. 89Zr-atezolizumab is currently in man, and early data show tumor targeting but also abundant uptake in several normal tissues. Therefore, we conducted a reverse translational study both to understand if tumor to normal tissue ratios for 89Zr-atezolizumab could be improved and to make direct comparisons to 89Zr-C4, a radiotracer that we showed can detect a large dynamic range of tumor-associated PD-L1 expression. PET/CT and biodistribution studies in tumor bearing immunocompetent and nu/nu mice revealed that high specific activity 89Zr-atezolizumab (∼2 μCi/μg) binds to PD-L1 on tumors but also results in very high uptake in many normal mouse tissues, as expected. Unexpectedly, 89Zr-atezolizumab uptake was generally higher in normal mouse tissues compared to 89Zr-C4 and lower in H1975, a tumor model with modest PD-L1 expression. Also unexpectedly, reducing the specific activity at least 15-fold suppressed 89Zr-atezo uptake in normal mouse tissues but increased tumor uptake to levels observed with high specific activity 89Zr-C4. In summary, these data reveal that low specific activity 89Zr-atezo may be necessary for accurately measuring PD-L1 in the tumor microenvironment, assuming a threshold can be identified that preferentially suppresses binding in normal tissues without reducing binding to tumors with abundant expression. Alternatively, high specific activity approaches like 89Zr-C4 PET may be simpler to implement clinically to measure the broad dynamic range of PD-L1 expression known to manifest among tumors." @default.
• W2889873881 created "2018-09-27" @default.
• W2889873881 creator A5012293034 @default.
• W2889873881 creator A5041557101 @default.
• W2889873881 creator A5043646384 @default.
• W2889873881 creator A5049214744 @default.
• W2889873881 creator A5054643240 @default.
• W2889873881 creator A5060245538 @default.
• W2889873881 creator A5060740747 @default.
• W2889873881 creator A5066159059 @default.
• W2889873881 creator A5073970384 @default.
• W2889873881 creator A5087001996 @default.
• W2889873881 date "2018-09-18" @default.
• W2889873881 modified "2023-10-18" @default.
• W2889873881 title "A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4" @default.
• W2889873881 cites W1969062072 @default.
• W2889873881 cites W2049553585 @default.
• W2889873881 cites W2124427232 @default.
• W2889873881 cites W2136196468 @default.
• W2889873881 cites W2136859769 @default.
• W2889873881 cites W2290610287 @default.
• W2889873881 cites W2475509424 @default.
• W2889873881 cites W2497521284 @default.
• W2889873881 cites W2560367415 @default.
• W2889873881 cites W2563163619 @default.
• W2889873881 cites W2605094777 @default.
• W2889873881 cites W2622499649 @default.
• W2889873881 cites W2741265240 @default.
• W2889873881 cites W2761797827 @default.
• W2889873881 cites W2767824485 @default.
• W2889873881 cites W2789314441 @default.
• W2889873881 cites W2801714672 @default.
• W2889873881 doi "https://doi.org/10.1021/acs.bioconjchem.8b00632" @default.
• W2889873881 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6430562" @default.
• W2889873881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30227708" @default.
• W2889873881 hasPublicationYear "2018" @default.
• W2889873881 type Work @default.
• W2889873881 sameAs 2889873881 @default.
• W2889873881 citedByCount "35" @default.
• W2889873881 countsByYear W28898738812019 @default.
• W2889873881 countsByYear W28898738812020 @default.
• W2889873881 countsByYear W28898738812021 @default.
• W2889873881 countsByYear W28898738812022 @default.
• W2889873881 countsByYear W28898738812023 @default.
• W2889873881 crossrefType "journal-article" @default.
• W2889873881 hasAuthorship W2889873881A5012293034 @default.
• W2889873881 hasAuthorship W2889873881A5041557101 @default.
• W2889873881 hasAuthorship W2889873881A5043646384 @default.
• W2889873881 hasAuthorship W2889873881A5049214744 @default.
• W2889873881 hasAuthorship W2889873881A5054643240 @default.
• W2889873881 hasAuthorship W2889873881A5060245538 @default.
• W2889873881 hasAuthorship W2889873881A5060740747 @default.
• W2889873881 hasAuthorship W2889873881A5066159059 @default.
• W2889873881 hasAuthorship W2889873881A5073970384 @default.
• W2889873881 hasAuthorship W2889873881A5087001996 @default.
• W2889873881 hasBestOaLocation W28898738812 @default.
• W2889873881 hasConcept C121608353 @default.
• W2889873881 hasConcept C12554922 @default.
• W2889873881 hasConcept C126322002 @default.
• W2889873881 hasConcept C185592680 @default.
• W2889873881 hasConcept C202751555 @default.
• W2889873881 hasConcept C2775949291 @default.
• W2889873881 hasConcept C2776107976 @default.
• W2889873881 hasConcept C2777701055 @default.
• W2889873881 hasConcept C2777807558 @default.
• W2889873881 hasConcept C2780057760 @default.
• W2889873881 hasConcept C3020616263 @default.
• W2889873881 hasConcept C502942594 @default.
• W2889873881 hasConcept C55493867 @default.
• W2889873881 hasConcept C71924100 @default.
• W2889873881 hasConcept C86803240 @default.
• W2889873881 hasConceptScore W2889873881C121608353 @default.
• W2889873881 hasConceptScore W2889873881C12554922 @default.
• W2889873881 hasConceptScore W2889873881C126322002 @default.
• W2889873881 hasConceptScore W2889873881C185592680 @default.
• W2889873881 hasConceptScore W2889873881C202751555 @default.
• W2889873881 hasConceptScore W2889873881C2775949291 @default.
• W2889873881 hasConceptScore W2889873881C2776107976 @default.
• W2889873881 hasConceptScore W2889873881C2777701055 @default.
• W2889873881 hasConceptScore W2889873881C2777807558 @default.
• W2889873881 hasConceptScore W2889873881C2780057760 @default.
• W2889873881 hasConceptScore W2889873881C3020616263 @default.
• W2889873881 hasConceptScore W2889873881C502942594 @default.
• W2889873881 hasConceptScore W2889873881C55493867 @default.
• W2889873881 hasConceptScore W2889873881C71924100 @default.
• W2889873881 hasConceptScore W2889873881C86803240 @default.
• W2889873881 hasFunder F4320306095 @default.
• W2889873881 hasFunder F4320306163 @default.
• W2889873881 hasFunder F4320337351 @default.
• W2889873881 hasFunder F4320337363 @default.
• W2889873881 hasIssue "10" @default.
• W2889873881 hasLocation W28898738811 @default.
• W2889873881 hasLocation W28898738812 @default.
• W2889873881 hasLocation W28898738813 @default.
• W2889873881 hasLocation W28898738814 @default.
• W2889873881 hasLocation W28898738815 @default.
• W2889873881 hasOpenAccess W2889873881 @default.
• W2889873881 hasPrimaryLocation W28898738811 @default.

• next